1National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 4) (PB 41 of 2017)

Image unavailable in extracted text

PB 41 of 2017

National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 4)

National Health Act 1953

I, LOUISE CLARKE, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated 30 May 2017

LOUISE CLARKE

Assistant Secretary

Pharmaceutical Evaluation Branch

Pharmaceutical Benefits Division

Department of Health

Part 1 Preliminary

1 Name of Determination

(1) This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2017 (No. 4).

(2) This Determination may also be cited as PB 41 of 2017.

2 Commencement

This Determination commences on 1 June 2017.

3 Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).

Schedule 1 Amendments

(Section 3)

[1] Schedule 1, after item dealing with Codeine

Omit

Colestipol

[2] Schedule 1, after item dealing with Essential amino acids formula with vitamins and minerals

Omit

Etanercept

[3] Schedule 1, after item dealing with Flupenthixol Decanoate

Omit

Fluphenazine Decanoate

Fluticasone

Insert

Fluticasone furoate with vilanterol

[4] Schedule 1, after item dealing with Romiplostim

Omit

Rosiglitazone

[5] Schedule 1, after item dealing with Zidovudine

Omit

Zonisamide

[6] Schedule 2, after item dealing with Flutamide

Insert

Fluticasone

Fluticasone with Salmeterol

[7] Schedule 2, after item dealing with Zolmitriptan

Insert

Zonisamide